Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MGD019 |
| Trade Name | |
| Synonyms | MGD-019|MGD 019|AEX-1344|AEX1344|lorigerlimab |
| Drug Descriptions |
MGD019 is a tetravalent, dual-affinity re-targeting (DART) protein that potentially inhibits PD-1 (PDCD1) and CTLA4, resulting in enhanced immune response against cancer cells expressing PD-1 and CTLA4 (Keystone Symposia Conference, 2019, Feb. 18-22, Abs nr: 1012). |
| DrugClasses | CTLA4 Inhibitor 4 Immune Checkpoint Inhibitor 150 |
| CAS Registry Number | NA |
| NCIT ID | C158505 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Docetaxel + MGD019 + Prednisone | Docetaxel MGD019 Prednisone | 0 | 1 |
| MGC018 + MGD019 | MGC018 MGD019 | 0 | 1 |
| MGD019 | MGD019 | 0 | 3 |
| MGD019 + Regorafenib | MGD019 Regorafenib | 0 | 3 |